Ads
related to: cancer marker levels after treatment- MET Biomarker Testing
Explore MET Biomarker Testing
Methodologies & Detection Methods
- Poor Prognosis In NSCLC
Learn about MET Biomarkers
and Poorer Prognosis in NSCLC
- MET Biomarker Prevalence
Explore MET Biomarkers
Prevalent in NSCLC
- MET Aberrations In NSCLC
Review the Current & Emerging MET
Biomarkers Prevalent in NSCLC
- MET Biomarker Testing
- 262 Neil Avenue # 430, Columbus, Ohio · Directions · (614) 221-7464
Search results
Results From The WOW.Com Content Network
The level of tumor marker should indicate the state of the malignancy to be able to monitor treatment response. An ideal tumor marker does not exist, and how they are clinically applied depends on the specific tumor marker. For example, tumor markers like Ki-67 can be used to choose form of treatment or in prognostics but are not useful to give ...
Progressive disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; Evaluation of non-target lesions. Complete response (CR): Disappearance of all non-target lesions and normalization of tumor marker level
Levels or presence of biomarker should readily distinguish between normal, cancerous, and precancerous tissue; Effective treatment of the cancer should change the level of the biomarker; Level of the biomarker should not change spontaneously or in response to other factors not related to the successful treatment of the cancer
Serum levels are useful in assessing response to treatment. [citation needed] Like any elevated tumor marker, elevated AFP by itself is not diagnostic, only suggestive. Tumor markers are used primarily to monitor the result of a treatment (e.g. chemotherapy). If levels of AFP go down after treatment, the tumor is not growing.
Minimal residual disease (MRD), also known as Molecular residual disease, is the name given to small numbers of cancer cells that remain in a person either during or after treatment when the patient is in remission (no symptoms or signs of disease). Sensitive molecular tests are either in development or available to test for MRD.
A subsequent increase in PSA levels by 2.0 ng/mL [disputed – discuss] above the nadir is the currently accepted definition of prostate cancer recurrence after radiation therapy. [citation needed] Recurrent prostate cancer detected by a rise in PSA levels after curative treatment is referred to as a "biochemical recurrence". The likelihood of ...